Skandinaviska Enskilda Banken (SEB)
NBIX icon

Skandinaviska Enskilda Banken (SEB)’s Neurocrine Biosciences NBIX Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-58,503
Closed -$8.3M – 511
2025
Q4 		$8.3M Sell
58,503
-2,615
-4% -$379K 0.03% 317
2025
Q3 		$8.58M Sell
61,118
-11,272
-16% -$1.53M 0.03% 312
2025
Q2 		$9.1M Sell
72,390
-70,371
-49% -$8.07M 0.04% 307
2025
Q1 		$15.8M Sell
142,761
-37,645
-21% -$4.77M 0.08% 209
2024
Q4 		$24.7M Sell
180,406
-123,436
-41% -$15.3M 0.11% 151
2024
Q3 		$35M Buy
303,842
+184,005
+154% +$25.2M 0.16% 112
2024
Q2 		$16.5M Buy
119,837
+2,877
+2% +$395K 0.08% 196
2024
Q1 		$16.1M Buy
116,960
+54,419
+87% +$7.43M 0.08% 209
2023
Q4 		$8.24M Buy
62,541
+22,559
+56% +$2.6M 0.05% 290
2023
Q3 		$4.5M Sell
39,982
-86,335
-68% -$9.09M 0.03% 377
2023
Q2 		$11.9M Sell
126,317
-58,378
-32% -$5.7M 0.08% 232
2023
Q1 		$18.7M Buy
184,695
+29,574
+19% +$3.08M 0.13% 171
2022
Q4 		$18.5M Sell
155,121
-1,663
-1% -$195K 0.14% 164
2022
Q3 		$16.7M Buy
156,784
+4,233
+3% +$430K 0.13% 155
2022
Q2 		$14.9M Sell
152,551
-2,702
-2% -$249K 0.11% 186
2022
Q1 		$14.6M Buy
155,253
+1,633
+1% +$138K 0.09% 212
2021
Q4 		$13M Sell
153,620
-114
-0.1% -$10.5K 0.07% 245
2021
Q3 		$14.7M Sell
153,734
-380
-0.2% -$35.9K 0.08% 231
2021
Q2 		$15M Buy
154,114
+16,585
+12% +$1.59M 0.09% 214
2021
Q1 		$13.4M Buy
137,529
+81,715
+146% +$8.57M 0.09% 223
2020
Q4 		$5.35M Sell
55,814
-356
-0.6% -$34.4K 0.04% 352
2020
Q3 		$5.4M Buy
56,170
+10,770
+24% +$1.25M 0.04% 322
2020
Q2 		$5.54M Buy
45,400
+6,000
+15% +$663K 0.04% 308
2020
Q1 		$3.41M Sell
39,400
-13,900
-26% -$1.36M 0.03% 355
2019
Q4 		$5.73M Buy
53,300
+5,900
+12% +$618K 0.05% 300
2019
Q3 		$4.27M Sell
47,400
-8,000
-14% -$747K 0.04% 350
2019
Q2 		$4.68M Buy
+55,400
New +$4.55M 0.04% 322

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s NBIX Position: Q1 2026 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 58,503 shares — an estimated $8.3M sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in NBIX in Q2 2019 and held it in 27 quarters. The position peaked at $35M in Q3 2024. 697 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Skandinaviska Enskilda Banken (SEB) reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
  • Skandinaviska Enskilda Banken (SEB) sold 58,503 Neurocrine Biosciences shares in Q1 2026, an estimated $8.3M.
  • Skandinaviska Enskilda Banken (SEB) first reported a position in Neurocrine Biosciences in Q2 2019 and held it in 27 quarters.
  • Skandinaviska Enskilda Banken (SEB)'s Neurocrine Biosciences position peaked at $35M in Q3 2024.
  • 697 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q1 2026, filed 15 May 2026.